Advertisement
Advertisement

LRMR

LRMR logo

Larimar Therapeutics, Inc. Common Stock

3.60
USD
Sponsored
-0.03
-0.96%
Jun 25, 12:37 UTC -4
Open

LRMR Earnings Reports

Positive Surprise Ratio

LRMR beat 26 of 39 last estimates.

67%

Next Report

Date of Next Report
Aug 12, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/
-$0.39
Implied change from Q1 26 (Revenue/ EPS)
--
/
+25.81%
Implied change from Q2 25 (Revenue/ EPS)
--
/
-4.88%

Larimar Therapeutics, Inc. Common Stock earnings per share and revenue

On May 14, 2026, LRMR reported earnings of -0.31 USD per share (EPS) for Q1 26, beating the estimate of -0.54 USD, resulting in a 43.19% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -0.75% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 10 analysts forecast an EPS of -0.39 USD, with revenue projected to reach -- USD, implying an increase of 25.81% EPS, and increase of 0.00% in Revenue from the last quarter.
FAQ
For Q1 2026, Larimar Therapeutics, Inc. Common Stock reported EPS of -$0.31, beating estimates by 43.19%, and revenue of $0.00, 0% as expectations.
The stock price moved down -0.75%, changed from $4.00 before the earnings release to $3.97 the day after.
The next earning report is scheduled for Aug 12, 2026.
Based on 10 analysts, Larimar Therapeutics, Inc. Common Stock is expected to report EPS of -$0.39 and revenue of -- for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement